Atherothrombosis in acute coronary syndromes: Mechanisms, markers, and mediators of vulnerability

Mount Sinai Journal of Medicine

Volumn 73, Issue 1, 2006, Pages 431-439

  Wasserman, Eric J ^a,b   Shipley, Neal M ^a,b  

^a JERSEY CITY MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; Inflammation; Markers; Mediators; Vulnerable

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; APOLIPOPROTEIN A; C REACTIVE PROTEIN; CD40 LIGAND; FIBRIN; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

ACUTE CORONARY SYNDROME; APOPTOSIS; ARTERY DIAMETER; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; EXTRACELLULAR MATRIX; FAMILIAL HYPERLIPEMIA; GENETIC RISK; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; INTRAVASCULAR ULTRASOUND; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; T LYMPHOCYTE; THROMBOGENICITY; THROMBOSIS; VASCULAR ENDOTHELIUM;

ACUTE DISEASE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CORONARY THROMBOSIS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; RISK FACTORS; SYNDROME;

EID: 32044443180     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 2004; 17(1):35-44.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
3. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet 1999; 353(Suppl 2):SII5-SII9.
4. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient. A call for new definitions and risk assessment strategies: part I. Circulation 2003; 108(14):1664-1672.
5. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657-671.
6. Ambrose JA, Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med 1996; 156:1382-1394.
7. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76:301-314.
8. Nakashima Y, Plump AS, Raines EW, et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14(1):133 -140.
9. Springer TA, Cybulsky MI. Traffic signals on endothelium for leukocytes in health, inflammation, and atherosclerosis. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven; 1996. pp. 511-538.
10. Werb Z, Banda MJ, Jones PA. Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins, and collagen by proteinases isolated from macrophages. J Exp Med 1980; 152:1340-1357.
11. Agrotis A, Kalinina N, Bobik A. Transforming growth factor-beta, cell signaling and cardiovascular disorders. Curr Vasc Pharmacol 2005; 3:55-61.
12. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336(18):1276-1282.
13. Ridker P, Vaughan D, Stampfer M, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341(8859):1165-1168.
14. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 1997; 17:1859-1867.
15. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-2503.
16. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316(22):1371-1375.
17. Barger AC, Beeuwkes R III, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries: a possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984; 310:175-177.
18. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103:934-940.
19. Smits PC, Pasterkamp G, de Jaegere PJ, et al. Coronary artery disease: arterial remodeling and clinical presentation. Heart 1999;82:461-464.
20. Pasterkamp G, Wensing PJW, Post MJ, et al. Paradoxical arterial wall shrinkage contributes to luminal narrowing of human atherosclerotic femoral arteries. Circulation 1995; 91:1444-1449.
21. Pasterkamp G, de Kleijn D, Fitzgerald P. Expansive remodeling, a sheep in wolf's clothes. J Vasc Res 2002; 39:514-523.
22. Schoenhagen P, Ziada KM, Kapadia SR, et al. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes. Circulation 1999; 101:598-603.
23. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53(4):363-373.
24. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262-1175.
25. Frink R. Chronic ulcerated plaques - new insights into the pathogenesis of acute coronary disease. J Invasive Cardiol 1994; 6:173-185.
26. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999; 82:265-268.
27. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc Med 1998; 3(3):231-229.
28. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262-1275.
29. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995; 332:512-521.
30. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2:941-944.
31. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol, 1996; 77(14):1179-1184.
32. Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol 2000; 15:416-421.
33. Loscalzo J. Lipoprotein (a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10:672-679.
34. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of the clinical presentation. J Am Coll Cardiol 1998; 32:2035-2042.
35. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003; 14:361-366.
36. Angles-Cano E, de la Pena Diaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001; 936:261-275.
37. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004; 24:1-8.
38. Laursen JB, Rajagopalan S, Galis Z, et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95:588-593.
39. Chobanian AV, Dzau VJ. Renin angiotensin system and atherosclerotic vascular disease. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven; 1996. pp. 237-242.
40. Mervaala EM, Muller DN, Park JK, et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999; 33:389-395.
41. Keidar S, Heinrich R, Kaplan M, et al. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol 2001; 21:1464-469.
42. AbdAlla S, Lother H, Langer A, et al. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 2004; 119(3):343-354.
43. Thomas WG. Double trouble for type 1 angiotensin receptors in atherosclerosis. N Engl J Med 2005; 352:506-568.
44. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5):383-393.
45. Osende JI, Badimon JJ, Fuster V, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38(5):1307-1312.
46. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952-957.
47. Rauch U, Crandall J, Osende JI, et al. Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. Am J Cardiol 2000; 86(2):246-249.
48. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002; 25(3):542-549.
49. Nowak J, Murray JJ, Oates JA, et al. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987; 76:6-14.
50. Reilly M, Delanty N, Lawson JA, Fitzgerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94:19-25.
51. Rauch U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001; 134:224-238.
52. Sanderson KJ, van Rij AM, Wade CR, Sutherland WHF. Lipid peroxidation of circulating low density lipoproteins with age, smoking and in peripheral vascular disease. Atherosclerosis 1995; 118:45-51.
53. Weber C, Erl W, Weber K, Weber PC. Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation 1996; 93:1488-1492.
54. Zeiher AM, Schaechinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995; 92:1094-1100.
55. Ikarugi H, Yamashita T, Aoki R, et al. Impaired spontaneous thrombolytic activity in elderly and in habitual smokers, as measured by a new global thrombosis test. Blood Coagul Fibrinolysis 2003; 14(8):781-784.
56. Newby DE, McLeod AL, Uren NG, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001; 103:1936-1941.
57. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95:594-959.
58. Jang IK, Gold HK, Leinbach RC, et al. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arterioscler Thromb 1992; 12(8):948-954:
59. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99:1780-1787.
60. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res 2002; 53:313-325.
61. Kockx MM, Herman AG. Apoptosis in atherogenesis: implications for plaque destabilization. Eur Heart J 1998; 19 Suppl G:G23-G28.
62. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001; 88:998-1003.
63. Bauriedel G, Hutter R, Welsch U, et al. Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability. Cardiovasc Res 1999; 41(2):480-488.
64. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338(15):1042-1050.
65. Nygård O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230236.
66. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149-1155.
67. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268(7):877-881.
68. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91:2873-2879.
69. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58:731-741.
70. Tawakol A, Omland T, Gerhard M, et al. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95:1119-1121.
71. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272(27):17012-17017.
72. Guo X, Dudman NP. Homocysteine alters monocyte-endothelial interaction in vitro. Chin Med J (Engl) 2003; 116(1):34-38.
73. Blom HJ, Kleinveld HA, Boers GH, et al. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 1995; 25:149-54.
74. Rasmussen LM, Hansen PR, Ledet T. Homocysteine and the production of collagens, proliferation and apoptosis in human arterial smooth muscle cells. APMIS 2004; 112(9):598-604.
75. Tousoulis D, Davies G, Stefanadis C, et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89:993-997.
76. Paoletti R, Gotto AM, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation 2004; 109 Suppl III:20-26.
77. Blake GJ, Ridker PM. Inflammatory biomarkers and cardiovascular risk prediction. J Intern Med 2002; 252:283-294.
78. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331:417-424.
79. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive, protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103:2531-2534.
80. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336(14):973-979.
81. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. New Engl J Med 2005; 352:20-28.
82. Evans RM. The steroid and thyroid hormone receptor super-family. Science 1988; 240:889-895.
83. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Cell Dev Biol 2004; 20:455-480.
84. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996; 12:335-363.
85. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94:1168-1178.
86. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
87. Kato K, Yamada D, Midorikawa S, et al. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. Metabolism 2000; 49:662-665.
88. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998; 95:7614-7619.
89. Galis ZS, Sukhova GK, Kranzhofer R, et al. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995; 92(2):402-406.
90. Lendon CL, Davies MJ, Born GVR, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis 1991; 87:87-90.
91. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB 1991; 5:2145 -2154.
92. Smeglin A, Frishman WH. Elastinolytic matrix metalloproteinases and their inhibitors as therapeutic targets in atherosclerotic plaque instability. Cardiol Rev 2004; 12:141-150.
93. Matter H, Schudok M. Recent advances in the design of matrix metalloprotease inhibitors. Curr Opin Drug Discov Devel 2004; 7:513-535.
94. Armstrong DG, Jude EB. The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc 2002; 92(1):12-18.
95. Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004; 24(1):54-60.
96. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391(6667):591-594.
97. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394:200-203.
98. Heeschen C, Dimmeler S, Hamm CW, et al.; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348(12):1104-1111.
99. Hermann A, Rauch BH, Braun M, et al. Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12:74-82.
100. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003; 107:1123-1128.
101. Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother 2004; 38(9):1500-1508.